Trials / Conditions / Extensively Drug-Resistant Tuberculosis

Extensively Drug-Resistant Tuberculosis

12 registered clinical trials studyying Extensively Drug-Resistant Tuberculosis — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Economic Evaluation of New MDR TB Regimens NCT04207112	Medecins Sans Frontieres, Netherlands	Phase 2 / Phase 3
Completed	Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short NCT04062201	Wits Health Consortium (Pty) Ltd	Phase 3
Unknown	PRACTECAL-PKPD Sub Study NCT04081077	Medecins Sans Frontieres, Netherlands	Phase 2 / Phase 3
Completed	Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tub NCT03086486	Global Alliance for TB Drug Development	Phase 3
Completed	Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) NCT02589782	Medecins Sans Frontieres, Netherlands	Phase 2 / Phase 3
Completed	An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis NCT02454205	University of Cape Town	Phase 2 / Phase 3
Completed	Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients NCT01521364	University Medical Center Groningen	Phase 4
Recruiting	Training Protocol on the Natural History of Tuberculosis NCT01212003	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	Tuberculosis in China NCT01071603	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB NCT00664313	Centers for Disease Control and Prevention	Phase 1 / Phase 2
Completed	Linezolid to Treat Extensively-Drug Resistant Tuberculosis NCT00727844	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tube NCT00685360	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 2